{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T01:13:23Z","timestamp":1772673203920,"version":"3.50.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T00:00:00Z","timestamp":1759536000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Huilan Public Welfare-Haosen Pharmaceutical Lung Cancer Precision Medicine Research Special Fund - Real World Study on Amatitinib Treatment for EGFRm NSCLC","award":["HL-HS2020-21"],"award-info":[{"award-number":["HL-HS2020-21"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Naunyn-Schmiedeberg's Arch Pharmacol"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1007\/s00210-025-04555-4","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T07:54:04Z","timestamp":1759564444000},"page":"3673-3681","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nutritional status and drug resistance in EGFR-mutant NSCLC: a retrospective cohort study on almonertinib efficacy"],"prefix":"10.1007","volume":"399","author":[{"given":"Chao","family":"Wu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ying","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuxing","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuning","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bangjie","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fenglin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ziran","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Congjun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,10,4]]},"reference":[{"issue":"1","key":"4555_CR1","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.clnu.2016.07.015","volume":"36","author":"J Arends","year":"2017","unstructured":"Arends J, Bachmann P, Baracos V et al (2017) ESPEN guidelines on nutrition in cancer patients. Clin Nutr (Edinburgh, Scotland) 36(1):11\u201348. https:\/\/doi.org\/10.1016\/j.clnu.2016.07.015","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"4555_CR2","doi-asserted-by":"publisher","first-page":"17105","DOI":"10.1038\/nrdp.2017.105","volume":"4","author":"VE Baracos","year":"2018","unstructured":"Baracos VE, Martin L, Korc M, Guttridge DC, Fearon KCH (2018) Cancer-associated cachexia. Nat Rev Disease primers 4:17105. https:\/\/doi.org\/10.1038\/nrdp.2017.105","journal-title":"Nat Rev Disease primers"},{"issue":"5","key":"4555_CR3","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1038\/s41568-020-0251-4","volume":"20","author":"AK Biswas","year":"2020","unstructured":"Biswas AK, Acharyya S (2020) Understanding cachexia in the context of metastatic progression. Nat Rev Cancer 20(5):274\u2013284. https:\/\/doi.org\/10.1038\/s41568-020-0251-4","journal-title":"Nat Rev Cancer"},{"key":"4555_CR4","doi-asserted-by":"publisher","first-page":"105583","DOI":"10.1016\/j.phrs.2021.105583","volume":"167","author":"RF Dong","year":"2021","unstructured":"Dong RF, Zhu ML, Liu MM et al (2021) EGFR mutation mediates resistance to EGFR tyrosine kinase inhibitors in NSCLC: From molecular mechanisms to clinical research. Pharmacol Res 167:105583. https:\/\/doi.org\/10.1016\/j.phrs.2021.105583","journal-title":"Pharmacol Res"},{"issue":"1","key":"4555_CR5","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1186\/s12888-019-2427-6","volume":"20","author":"DA Dunstan","year":"2020","unstructured":"Dunstan DA, Scott N (2020) Norms for Zung\u2019s self-rating anxiety scale. BMC Psychiat 20(1):90. https:\/\/doi.org\/10.1186\/s12888-019-2427-6","journal-title":"BMC Psychiat"},{"issue":"5","key":"4555_CR6","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/s1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495. https:\/\/doi.org\/10.1016\/s1470-2045(10)70218-7","journal-title":"Lancet Oncol"},{"key":"4555_CR7","doi-asserted-by":"publisher","first-page":"1454","DOI":"10.1200\/go.21.00228","volume":"7","author":"CG Ferreira","year":"2021","unstructured":"Ferreira CG, Abadi MD, de Mendon\u00e7a BP et al (2021) Demographic and clinical outcomes of brazilian patients with stage III or IV non-small-cell lung cancer: real-world evidence study on the basis of deterministic linkage approach. JCO Global Oncology 7:1454\u20131461. https:\/\/doi.org\/10.1200\/go.21.00228","journal-title":"JCO Global Oncology"},{"issue":"7689","key":"4555_CR8","doi-asserted-by":"publisher","first-page":"446","DOI":"10.1038\/nature25183","volume":"553","author":"RS Herbst","year":"2018","unstructured":"Herbst RS, Morgensztern D, Boshoff C (2018) The biology and management of non-small cell lung cancer. Nature 553(7689):446\u2013454. https:\/\/doi.org\/10.1038\/nature25183","journal-title":"Nature"},{"issue":"9","key":"4555_CR9","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1016\/j.clnu.2019.11.041","volume":"39","author":"L Hersberger","year":"2020","unstructured":"Hersberger L, Bargetzi L, Bargetzi A et al (2020) Nutritional risk screening (NRS 2002) is a strong and modifiable predictor risk score for short-term and long-term clinical outcomes: secondary analysis of a prospective randomised trial. Clin Nutr (Edinburgh, Scotland) 39(9):2720\u20132729. https:\/\/doi.org\/10.1016\/j.clnu.2019.11.041","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"4555_CR10","doi-asserted-by":"publisher","first-page":"107667","DOI":"10.1016\/j.pharmthera.2020.107667","volume":"217","author":"H Himmerich","year":"2021","unstructured":"Himmerich H, Kan C, Au K, Treasure J (2021) Pharmacological treatment of eating disorders, comorbid mental health problems, malnutrition and physical health consequences. Pharmacol Ther 217:107667. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107667","journal-title":"Pharmacol Ther"},{"issue":"4","key":"4555_CR11","doi-asserted-by":"publisher","first-page":"1101","DOI":"10.1016\/j.chest.2021.12.655","volume":"161","author":"J Huang","year":"2022","unstructured":"Huang J, Deng Y, Tin MS et al (2022) Distribution, risk factors, and temporal trends for lung cancer incidence and mortality: a global analysis. Chest 161(4):1101\u20131111. https:\/\/doi.org\/10.1016\/j.chest.2021.12.655","journal-title":"Chest"},{"issue":"2","key":"4555_CR12","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.clnu.2022.12.011","volume":"42","author":"M Landgrebe","year":"2023","unstructured":"Landgrebe M, Tobberup R, Carus A, Rasmussen HH (2023) GLIM diagnosed malnutrition predicts clinical outcomes and quality of life in patients with non-small cell lung cancer. Clin Nutr (Edinburgh, Scotland) 42(2):190\u2013198. https:\/\/doi.org\/10.1016\/j.clnu.2022.12.011","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"issue":"27","key":"4555_CR13","doi-asserted-by":"publisher","first-page":"3162","DOI":"10.1200\/jco.21.02641","volume":"40","author":"S Lu","year":"2022","unstructured":"Lu S, Dong X, Jian H et al (2022) AENEAS: a randomized phase iii trial of aumolertinib versus gefitinib as first-line therapy for locally advanced or metastaticnon-small-cell lung cancer with EGFR Exon 19 deletion or L858R mutations. J Clin Oncol\u202f: Off J Am Soc Clin Oncol 40(27):3162\u20133171. https:\/\/doi.org\/10.1200\/jco.21.02641","journal-title":"J Clin Oncol : Off J Am Soc Clin Oncol"},{"issue":"3","key":"4555_CR14","doi-asserted-by":"publisher","first-page":"411","DOI":"10.1016\/j.jtho.2021.10.024","volume":"17","author":"S Lu","year":"2022","unstructured":"Lu S, Wang Q, Zhang G et al (2022) Efficacy of aumolertinib (HS-10296) in patients with advanced EGFR T790M+ NSCLC: updated post-national medical products administration approval results from the APOLLO registrational trial. J Thoracic Oncol\u202f: Off Publ Int Assoc Stud Lung Cancer 17(3):411\u2013422. https:\/\/doi.org\/10.1016\/j.jtho.2021.10.024","journal-title":"J Thoracic Oncol : Off Publ Int Assoc Stud Lung Cancer"},{"issue":"5","key":"4555_CR15","doi-asserted-by":"publisher","first-page":"2898","DOI":"10.1016\/j.clnu.2021.02.005","volume":"40","author":"M Muscaritoli","year":"2021","unstructured":"Muscaritoli M, Arends J, Bachmann P et al (2021) ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr (Edinburgh, Scotland) 40(5):2898\u20132913. https:\/\/doi.org\/10.1016\/j.clnu.2021.02.005","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"issue":"8","key":"4555_CR16","doi-asserted-by":"publisher","first-page":"595","DOI":"10.2174\/1568009619666181210114559","volume":"19","author":"T Nagano","year":"2019","unstructured":"Nagano T, Tachihara M, Nishimura Y (2019) Molecular mechanisms and targeted therapies including immunotherapy for non-small cell lung cancer. Curr Cancer Drug Targets 19(8):595\u2013630. https:\/\/doi.org\/10.2174\/1568009619666181210114559","journal-title":"Curr Cancer Drug Targets"},{"issue":"5","key":"4555_CR17","doi-asserted-by":"publisher","first-page":"448","DOI":"10.1097\/yco.0000000000000727","volume":"34","author":"AA Panjwani","year":"2021","unstructured":"Panjwani AA, Li M (2021) Recent trends in the management of depression in persons with cancer. Curr Opin Psychiatry 34(5):448\u2013459. https:\/\/doi.org\/10.1097\/yco.0000000000000727","journal-title":"Curr Opin Psychiatry"},{"key":"4555_CR18","doi-asserted-by":"publisher","first-page":"102308","DOI":"10.1016\/j.ctrv.2021.102308","volume":"101","author":"F Passiglia","year":"2021","unstructured":"Passiglia F, Bertaglia V, Reale ML et al (2021) Major breakthroughs in lung cancer adjuvant treatment: Looking beyond the horizon. Cancer Treat Rev 101:102308. https:\/\/doi.org\/10.1016\/j.ctrv.2021.102308","journal-title":"Cancer Treat Rev"},{"key":"4555_CR19","doi-asserted-by":"publisher","first-page":"1004282","DOI":"10.1002\/14651858.CD004282.pub3","volume":"9","author":"JR Rueda","year":"2011","unstructured":"Rueda JR, Sola I, Pascual A, SubiranaCasacuberta M (2011) Non-invasive interventions for improving well-being and quality of life in patients with lung cancer. Cochrane Database Syst Rev 9:1004282. https:\/\/doi.org\/10.1002\/14651858.CD004282.pub3","journal-title":"Cochrane Database Syst Rev"},{"key":"4555_CR20","doi-asserted-by":"publisher","first-page":"107088","DOI":"10.1016\/j.phrs.2024.107088","volume":"201","author":"C Shi","year":"2024","unstructured":"Shi C, Wang C, Fu Z et al (2024) Lipocalin 2 (LCN2) confers acquired resistance to almonertinib in NSCLC through LCN2-MMP-9 signaling pathway. Pharmacol Res 201:107088. https:\/\/doi.org\/10.1016\/j.phrs.2024.107088","journal-title":"Pharmacol Res"},{"issue":"1","key":"4555_CR21","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1073\/pnas.1808950116","volume":"116","author":"C Sun","year":"2019","unstructured":"Sun C, Li T, Song X et al (2019) Spatially resolved metabolomics to discover tumor-associated metabolic alterations. Proc Natl Acad Sci USA 116(1):52\u201357. https:\/\/doi.org\/10.1073\/pnas.1808950116","journal-title":"Proc Natl Acad Sci USA"},{"issue":"3","key":"4555_CR22","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: Cancer J Clin 71(3):209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA: Cancer J Clin"},{"key":"4555_CR23","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.2147\/cia.S201873","volume":"14","author":"Y Wang","year":"2019","unstructured":"Wang Y, Zhang R, Shen Y, Su L, Dong B, Hao Q (2019) Prediction of chemotherapy adverse reactions and mortality in older patients with primary lung cancer through frailty index based on routine laboratory data. Clin Interv Aging 14:1187\u20131197. https:\/\/doi.org\/10.2147\/cia.S201873","journal-title":"Clin Interv Aging"},{"issue":"12","key":"4555_CR24","doi-asserted-by":"publisher","first-page":"1907","DOI":"10.1016\/j.jtho.2020.09.001","volume":"15","author":"JC Yang","year":"2020","unstructured":"Yang JC, Camidge DR, Yang CT et al (2020) Safety, efficacy, and pharmacokinetics of almonertinib (HS-10296) in pretreated patients with EGFR-mutated advanced NSCLC: a multicenter, open-label, phase 1 trial. J Thoracic Oncol\u202f: Off Publ Int Assoc Study of Lung Cancer 15(12):1907\u20131918. https:\/\/doi.org\/10.1016\/j.jtho.2020.09.001","journal-title":"J Thoracic Oncol : Off Publ Int Assoc Study of Lung Cancer"},{"issue":"5","key":"4555_CR25","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1016\/j.cell.2007.11.013","volume":"131","author":"Y Yarden","year":"2007","unstructured":"Yarden Y, Shilo BZ (2007) SnapShot: EGFR signaling pathway. Cell 131(5):1018. https:\/\/doi.org\/10.1016\/j.cell.2007.11.013","journal-title":"Cell"},{"issue":"6","key":"4555_CR26","doi-asserted-by":"publisher","first-page":"4225","DOI":"10.1016\/j.clnu.2021.01.033","volume":"40","author":"Q Zhang","year":"2021","unstructured":"Zhang Q, Zhang KP, Zhang X et al (2021) Scored-GLIM as an effective tool to assess nutrition status and predict survival in patients with cancer. Clin Nutr (Edinburgh, Scotland) 40(6):4225\u20134233. https:\/\/doi.org\/10.1016\/j.clnu.2021.01.033","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"4555_CR27","doi-asserted-by":"publisher","first-page":"750031","DOI":"10.3389\/fphar.2021.750031","volume":"12","author":"Y Zhang","year":"2021","unstructured":"Zhang Y, Zhang Y, Niu W et al (2021) Experimental study of almonertinib crossing the blood-brain barrier in EGFR-mutant NSCLC brain metastasis and spinal cord metastasis models. Front Pharmacol 12:750031. https:\/\/doi.org\/10.3389\/fphar.2021.750031","journal-title":"Front Pharmacol"},{"key":"4555_CR28","doi-asserted-by":"publisher","first-page":"833929","DOI":"10.3389\/fendo.2022.833929","volume":"13","author":"Q Zhang","year":"2022","unstructured":"Zhang Q, Liu H, Yang J (2022) Aumolertinib effectively reduces clinical symptoms of an EGFR L858R-mutant non-small cell lung cancer case coupled with osimertinib-induced cardiotoxicity: case report and review. Front Endocrinol 13:833929. https:\/\/doi.org\/10.3389\/fendo.2022.833929","journal-title":"Front Endocrinol"},{"issue":"10","key":"4555_CR29","doi-asserted-by":"publisher","first-page":"867","DOI":"10.21037\/atm-21-1606","volume":"9","author":"C Zhou","year":"2021","unstructured":"Zhou C, Xie L, Liu W et al (2021) Absorption, metabolism, excretion, and safety of [(14)C]almonertinib in healthy Chinese subjects. Ann Transl Med 9(10):867. https:\/\/doi.org\/10.21037\/atm-21-1606","journal-title":"Ann Transl Med"}],"updated-by":[{"DOI":"10.1007\/s00210-025-04898-y","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:00:00Z","timestamp":1772668800000}}],"container-title":["Naunyn-Schmiedeberg's Archives of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00210-025-04555-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00210-025-04555-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T00:45:42Z","timestamp":1772671542000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00210-025-04555-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,4]]},"references-count":29,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["4555"],"URL":"https:\/\/doi.org\/10.1007\/s00210-025-04555-4","relation":{},"ISSN":["0028-1298","1432-1912"],"issn-type":[{"value":"0028-1298","type":"print"},{"value":"1432-1912","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,4]]},"assertion":[{"value":"22 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 August 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 March 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised: The institutions of Chao Wu and Ziran Zhang are incorrect.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 March 2026","order":8,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":9,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":10,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1007\/s00210-025-04898-y","URL":"https:\/\/doi.org\/10.1007\/s00210-025-04898-y","order":11,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Medical Ethics Committee of the First Clinical Medical College (First Affiliated Hospital) (PJ2023-08\u201335).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent of participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}